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ABSTRACT 
INTRODUCTION: Circulating lipoprotein (a) (Lp(a)) is a recognized risk factor for 
cardiovascular disease (CVD). Tibolone, a synthetic steroid, may lower Lp(a) levels; however, 
evidence of the effects of tibolone on Lp(a) still remain to be defined. Therefore, we investigated 
the effects of tibolone treatment on circulating Lp(a) levels in postmenopausal women. 
METHODS: The search included PUBMED, Web of Science, Scopus, and Google Scholar (up 
to January 31st, 2015) to identify controlled clinical studies investigating the effects of oral 
tibolone treatment on Lp(a) levels in postmenopausal women. Random-effects meta-regression 
was performed using unrestricted maximum likelihood method for the association between 
calculated weighted mean difference (WMD) and potential moderators. 
RESULTS: Meta-analysis of data from 12 trials (16 treatment arms) suggested a significant 
reduction of Lp(a) levels following tibolone treatment (WMD: -25.28%, 95% confidence interval 
[CI]: -36.50, -14.06; p<0.001). This result was robust in the sensitivity analysis and its 
significance was not influenced after omitting each of the included studies from the meta-
analysis. When the studies were categorized according to the tibolone dose, there were consistent 
significant reductions of Lp(a) in the subsets of studies with doses <2.5 mg/day (WMD:                  
-17.00%, 95%CI: -30.22, -3.77; p<0.012) and 2.5 mg/day (WMD: -29.18%, 95%CI: -45.02,           
-13.33; p<0.001). Likewise, there were similar reductions in the subsets of trials with follow-up 
either <24 months (WMD: -26.79%, 95%CI: -38.40, -15.17; p<0.001) or ≥24 months (WMD: -
23.10%, 95%CI: -40.17, -6.03; p=0.008).  
CONCLUSIONS: This meta-analysis shows that oral tibolone treatment significantly lowers 
circulating Lp(a) levels in postmenopausal women. Further studies are warranted to explore the 
mechanism of this effect and the potential value and place of tibolone or its analogues in the 
treatment of elevated Lp(a) in individuals at risk of CVD. 
 
Keywords: cardiovascular disease, cardiovascular risk, lipoprotein(a), tibolone.  
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INTRODUCTION 
Lipoprotein(a) (Lp(a)) is a unique lipoprotein particle, which consists of an apolipoprotein B 
containing  lipoprotein moiety very similar to low-density lipoprotein (LDL) covalently linked to 
the glycoprotein component apoprotein(a) [apo(a)] 1. Apo(a) is exclusively produced in the liver, 
and its secretions highly correlated with circulating Lp(a) levels 2. Clinical and epidemiological 
evidence reveals an increased level of Lp(a) to be a causal, independent risk factor for 
cardiovascular disease (CVD) 3-6. The atherogenic properties of Lp(a) are associated with several 
mechanisms, including the inhibition of the fibrinolitic system by homologous structure of 
apo(a) with plasminogen 7, the interaction with extracellular matrix conjugates such as 
glycoproteins 8, the binding to scavenger receptors on macrophages 9, 10, and the induction of 
inflammatory molecules 11. 
Given the above, there has been an interest in Lp(a) as a target for residual risk therapy 12-14. 
In general, circulating Lp(a) levels are genetically determined 15, while the levels can change in 
certain  circumstances, such as under acute vascular and inflammatory pathologies 16-18. The 
European Atherosclerosis Society (EAS) Consensus Panel recommends screening for elevated 
Lp(a) in those at intermediate or high CVD/coronary heart disease (CHD) risk, a desirable level 
<50 mg/dL as a function of global CV risk, and use of niacin for Lp(a) and CVD/CHD risk 
reduction 19. Since currently available LDL cholesterol-lowering drugs, such as statins, have 
little effects of Lp(a), and other, such as niacin is poorly tolerated and is not available in many 
countries, there has been a continuous search for effective agents for lowering circulating Lp(a) 
levels 20. 
Tibolone (Livial, Org OD 14) is a synthetic steroid with estrogenic, androgenic and 
progestogenic properties, and used orally for the prevention of osteoporotic bone loss and 
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hormonal replacement treatment on climacteric symptoms in postmenopausal women 21, 22. 
Tibolone itself has no activities, but two estrogenic metabolites (3α- and 3β-hydroxy [OH] 
tibolone) and the third metabolite (∆4-tibolone) exert the effects on climacteric symptoms, and 
the third metabolite also exerts additional progestogenic effects in endometrium 23, 24. Tibolone 
treatment can modulate the lipid profile and its possible reduction of Lp(a) has been observed 25, 
although the effects of tibolone on Lp(a) were not previously analysed within systematic review 
and meta-analysis 22. Therefore, we performed a meta-analysis to evaluate the efficacy of 
tibolone treatment on circulating Lp(a) levels in postmenopausal women. 
 
MATERIAL AND METHODS 
Search Strategy 
This study was designed according to the guidelines of the 2009 preferred reporting items 
for systematic reviews and meta-analysis (PRISMA) statement 26. PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed), Web of Science (http://apps.webofknowledge.com), 
SCOPUS (http://www.scopus.com), and Google Scholar (http://www.scholar.google.com) 
databases were searcher and the search was limited to the controlled studies (mainly randomized 
controlled trials [RCTs], as well as controlled clinical trials, perspective and open-label studies) 
carried out up to January 31, 2014, investigating the potential effects of tibolone treatment on 
Lp(a) concentrations in the group of postmenopausal women. The databases were searched using 
the following search terms in titles and abstracts (also in the combination with MESH terms): 
(tibolone OR OrgOD14 OR “Org OD14” OR livial OR livial®) AND (lipoprotein(a) OR 
“lipoprotein (a)” OR Lp(a) OR “Lp(a)”). The wild-card term ‘‘*’’ was used to increase the 
sensitivity of the search strategy. No language restriction was used in the literature search. The 
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search was limited to studies in humans. Selected articles were searched to identify further 
relevant studies. Two reviewers (KK and AS) evaluated each article separately. Disagreements 
were resolved by agreement and discussion with a third party (MB). 
 
Study Selection 
Original studies (all in postmenopausal women) were included if they met the following 
inclusion criteria: (i) being a controlled clinical study (RCT, controlled perspective or open-label 
study), (ii) investigating the impact of tibolone on plasma/serum concentrations of Lp(a), (iii) 
presentation of sufficient information on Lp(a) concentrations at baseline and at the end of 
follow-up in each group or providing the net change values.  
Exclusion criteria were: (i) lack of a an appropriate control group in the study design, (ii) 
non-clinical observational studies with case-control, cross-sectional or cohort design, (iii) lack of 
sufficient information on baseline or follow-up Lp(a) concentrations, (iv) inability to obtain 
adequate details of study methodology or results from the article or the investigators, and, (v) the 
study was ongoing. 
  
Data extraction  
Eligible studies were reviewed and the following data were abstracted: 1) first author's 
name; 2) year of publication; 3) study location; 4) study design; 5) tibolone dose and the route of 
administration; 6) number of participants in the tibolone and control groups; 7) inclusion and 
exclusion criteria; 8) age, gender and body mass index (BMI) of study participants; 9) prevalence 
of diabetes mellitus; and 10) baseline and follow-up plasma concentrations of Lp(a). 
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Quality assessment 
A systematic assessment of bias in the included studies was performed using the Cochrane 
criteria 27. The items used for the assessment of each study were as follows: adequacy of 
sequence generation, allocation concealment, blinding, addressing of dropouts (incomplete 
outcome data), selective outcome reporting, and other potential sources of bias. According to the 
recommendations of the Cochrane Handbook, a judgment of “yes” indicated low risk of bias, 
while “no” indicated high risk of bias. Labeling an item as “unclear” indicated an unclear or 
unknown risk of bias. 
  
Quantitative Data Synthesis 
Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software 
(Biostat, NJ) 28. Net changes in measurements (change scores) were calculated as follows: 
measure at end of follow-up − measure at baseline. For cross-over trials, net change in plasma 
concentrations of Lp(a) were calculated by subtracting the value after control intervention from 
that reported after treatment. All values were collated in percentage changes from baseline 
levels. Standard deviations (SDs) of the mean difference were calculated using the following 
formula: SD = square root [(SDpre-treatment)2 + (SDpost-treatment)2 – (2R × SDpre-treatment × SDpost-
treatment)], assuming a correlation coefficient (R) = 0.5. If the outcome measures were reported in 
median and inter-quartile range, mean and standard SD values were estimated using the method 
described by Hozo et al. 29. Where standard error of the mean (SEM) was only reported, standard 
deviation (SD) was estimated using the following formula: SD = SEM × square root (n), where n 
is the number of subjects. When the results were presented in multiple time points, only data 
relating to the longest duration of treatment were considered. 
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A random-effects model (using DerSimonian-Laird method) and the generic inverse 
variance method were used to compensate for the heterogeneity of studies in terms of 
demographic characteristics of populations being studied and also differences in study design. 
Heterogeneity was quantitatively assessed using I2 index. Effect sizes were expressed as 
weighted mean difference (WMD) and 95% confidence interval (CI). In order to evaluate the 
influence of each study on the overall effect size, sensitivity analysis was conducted using leave-
one-out method, i.e. removing one study each time and repeating the analysis 30, 31. 
 
Meta-regression 
Random-effects meta-regression was performed using unrestricted maximum likelihood 
method to evaluate the association between calculated WMD and potential moderators including 
duration of treatment with tibolone. 
 
Publication bias 
Potential publication bias was explored using visual inspection of Begg’s funnel plot 
asymmetry, fail-safe N test, and Begg’s rank correlation and Egger’s weighted regression tests. 
Duval & Tweedie “trim and fill” method was used to adjust the analysis for the effects of 
publication bias 32. 
 
RESULTS 
The search provided 82 articles excluding duplicates. Of those, 67 were excluded after initial 
screening and the remaining 15 full text papers were reviewed. Finally 12 were scrutinized as 
full texts and were selected to be included in the analysis 33-44. The reasons for excluding the 
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remaining 3 articles were: not controlled for tibolone (n=2) and no tibolone treatment arm (n=1) 
(Figure 1). In total, 1009 participants were randomized, of whom 634 were allocated to tibolone 
supplementation group and 375 to control group in the selected studies. The number of 
participants in these studies ranged from 6 to 136. They were published between 1996 and 2009, 
and were conducted in USA, Greece, Ireland, the Netherlands (3 trials), Italy (2 trials), UK, 
Serbia and Turkey. A range of tibolone doses from 0.3 to 2.5 mg/day was administered in the 
included trials. Duration of supplementation with tibolone ranged between 3 and 60 months. 
Tibolone was safe and well-tolerated in all included studies with no report of any drug-related 
adverse events. Baseline parameters of the included studies are shown in Table 1.  
 
Risk of bias assessment 
According to the Cochrane Collaboration 45, a specific tool for assessing risk of bias in each 
involved study comprises judgment of specific features of the study. This involves evaluating the 
risk of bias as ‘low risk’, ‘high risk or ‘unclear risk’. The last category shows either lack of 
information or uncertainty over the potential for bias. There are seven analyzed domains 
comprising: sequence generation (selection bias), allocation sequence concealment (selection 
bias), blinding of participants and personnel (performance bias), blinding of outcome assessment 
(detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting 
bias) and other potential sources of bias (Table 2). 
 
Effect of tibolone on plasma Lp(a) concentrations 
Overall, the impact of tibolone on plasma Lp(a) concentrations were reported in 12 trials 
comprising 16 treatment arms with 1009 women-patients. The results suggested a significant 
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reduction of Lp(a) levels following treatment with tibolone (WMD: -25.28%, 95%CI: -36.50, -
14.06; p < 0.001), which are robust in the sensitivity analysis, and their significance was not 
influenced after omitting each of the included studies from meta-analysis (Figure 2). When the 
studies were categorized according to the dose of treatment, there was consistent significant 
reduction in Lp(a) concentrations in the subsets of trials with doses <2.5 mg/day (WMD: -
17.00%, 95%CI: -30.22, -3.77; p < 0.012) and =2.5 mg/day (WMD: -29.18%, 95%CI: -45.02, -
13.33; p < 0.001) (Figure 3). Likewise, there were similar reductions in the subsets of trials 
lasting either <24 months (WMD: -26.79%, 95%CI: -38.40, -15.17; p<0.001) or ≥24 months 
(WMD: -23.10%, 95%CI: -40.17, -6.03; p=0.008) (Figure 4). 
 
Meta-regression 
Random-effects meta-regression was performed to assess if the Lp(a) response to tibolone is 
associated with administered dose and duration of treatment. The results did not suggest any 
significant association between the changes in plasma concentrations of Lp(a) with dose (slope:   
-6.07; 95%CI: -20.16, 8.02; p = 0.399) and duration of treatment (slope: 0.27; 95%CI: -0.53, 
1.08; p = 0.505).  
 
Publication bias 
The funnel plot of the study standard error by effect size (WMD) was symmetric, suggesting 
lack of publication bias in the analysis of the effect tibolone on plasma Lp(a) concentrations. 
This finding was confirmed by the results of Egger’s linear regression (intercept = -3.04, 
standard error = 1.72; 95%CI: -6.73, 0.65, t = 1.77, df = 14, two-tailed p = 0.099) and Begg’s 
rank correlation tests (Kendall’s Tau with continuity correction = -0.24, z = 1.31, two-tailed             
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p-value = 0.192) (Figure 5). The “fail-safe N” test suggested that 523 studies would be needed to 
bring the effect size down to a non-significant (p > 0.05) value. 
 
DISCUSSION 
The present meta-analysis of data from 12 trials comprising 16 treatment arms revealed that 
oral tibolone treatment significantly reduced circulating Lp(a) levels in postmenopausal women. 
These results are of high importance because Lp(a) is  an independent risk factor for CVD, there 
are no effective and safe treatments for high Lp(a) levels, and postmenopausal women are at 
higher CVD risk 3-5.  
Tibolone treatment can reduce circulating Lp(a) levels by 25% (42-44). More recently, 
significant reductions of Lp(a) have been shown with a range of new therapies, including  
cholesteryl ester transfer protein (CETP) inhibitors, sequence-specific antisense oligonucleotides 
against apoB, inhibitory monoclonal antibodies to proprotein convertase subtilisin/kexin type-9 
(PCSK9), thyroid hormone analogues, and synthetic inhibitors of microsomal triglyceride 
transfer protein 46-51. The magnitude of reductions of Lp(a) by these drugs appears to be  similar 
to the ones with tibolone, while the overall magnitude of these recent drugs is still not 
established 46-48, 52. The magnitude of reduction of Lp(a) with  tibolone is similar to that of niacin. 
The influences of the dose and duration of used drugs on Lp(a) is also of concern 25. Niacin can 
reduce Lp(a) in a dose-dependent manner 53. Whereas, the present meta-analysis did not find a 
dose- or duration-dependent manner of tibolone treatment on Lp(a). This may be an advantage in 
using tibolone to decrease Lp(a) levels. 
The reduction of circulating Lp(a) by tibolone is still incompletely explained. The estrogenic 
property of tibolone is a possible explanation of the reduction of Lp(a) 25;  however, the details in 
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the involvement of estrogens in the Lp(a) regulation still remain to be fully clarified 54. One of 
the mechanism potentially responsible might be the fact that Lp(a) gene has an estrogen response 
element and tibolone may active this and reduce hepatic output of Apo(a) 55. Lp(a) is also 
decreased by testosterone and the androgenic component of tibolone may have a dual effect 56. 
However, further studies of the mechanism of action of tibolone on Lp(a) metabolism are still 
required. 
The present meta-analysis has limitations. First, the studies included in the present meta-
analysis were not always interventional studies focused on the Lp(a) levels, as a main endpoint, 
therefore well-designed interventional trials specific for Lp(a) are still necessary. Next, the 
included studies did not evaluate the long-term CVD outcomes associated with Lp(a) reduction. 
The reduction of Lp(a) is theoretically thought to be favorable for the prevention of the events, 
but whether the reduction of Lp(a) with Lp(a)-targeted therapies can lead to the favorable 
outcomes still needs to be proven, especially that available long-term controlled studies with a 
Lp(a)-lowering drug (nicotinic acid plus laropiprant) have failed to find a positive impact of the 
Lp(a) reduction on CV events 19. Some studies have also indicated that very low Lp(a) levels 
might be harmful 57, 58, however Mendelian randomization studies did not confirm that low Lp(a) 
increases the risk of diabetes 59. However, tibolone can improve not only Lp(a) level but also 
vascular functions (e.g. vasodilation) with its estrogenic property 21. Additionally, tibolone is 
reported to modulate other lipoprotein factors, i.e. the drug with its androgenic properties can 
reduce high-density lipoprotein cholesterol (HDL-C) as an unfavorable change 25. However, 
there are findings that the change of HDL-C is usually transient 33; on the other hand there are 
more and more data that we should not focus on HDL-C as it is not main target of the lipid-
lowering therapy, also due to the lasting debate on HDL functionality in different patients’ 
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groups 42, 60, 61. It should be emphasized that data on circulating Lp(a) levels were obtained from 
studies using different assays for Lp(a). It would be also necessary to look at the tibolone effects 
in general, including the influence on inflammatory markers, and other risk factors of CVD (e.g. 
blood pressure) 62, in order to finally confirm the possible benefits of its therapy. Finally, the 
included studies did not particularly focus on tibolone therapy-related side effects. One should 
notice that the side effects after tibolone therapy with doses ≤2.5 mg/day are uncommon 63. In 
the Long-Term Intervention on Fractures with Tibolone (LIFT) trial 64 in older postmenopausal 
women (aged 60-85 years) tibolone therapy (in comparison to placebo) significantly reduced the 
risk of vertebral and nonvertebral fractures, invasive breast cancer and colon cancer, however, 
increased of the stroke risk. There were also no significant differences in the risk of either CHD 
or venous thromboembolism 64. However the above mentioned stroke risk was not observed in 
other studies with younger postmenopausal women 65, 66.   
In conclusion, the present meta-analysis revealed that oral tibolone treatment significantly 
reduced circulating Lp(a) levels in postmenopausal women. The significance of this metabolic 
effect for the prevention of CVD needs to be weighed against other effects of tibolone and 
requires further investigations. Large-scale, well-designed studies may then be justified to 
explore the value of tibolone treatment in high risk subjects with elevated plasma Lp(a) levels 19. 
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TABLES  
Table 1. Demographic characteristics of the included studies 
Study 
 
 Bjarnaso
n et al. 33 
Gallagher 
et al. 34 
Kalogeropou-
los et al. 35 
Kroiss et 
al.36  
Lloyd et al. 
37
 
Milner et al. 
38
 
Ostberg et 
al. 39 
Perrone 
et al.40  
Von 
Eckardstein 
et al. 41 
Von 
Eckardstein 
et al. 42 
Anedda et 
al.43  
Demirol 
et al. 44 
Year  1997 2001 2004 2005 2000 1996 2004 2009 2001 2003 2003 2007 
Location  Netherlan
ds 
USA Greece Netherlands UK Ireland Serbia Italy Netherlands Germany Italy Turkey 
Design  Randomi
zed 
double-
blind, 
placebo 
controlled 
study 
Randomiz
ed, 
double-
blind, 
placebo 
controlled
, dose-
finding 
studies 
Clinical 
controlled trial 
Randomized
, double-
blind, 
placebo-
controlled, 
pilot study 
Randomized 
double-blind, 
placebo-
controlled 
study 
Randomized 
placebo-
controlled, 
pilot study 
One-year 
open-label  
controlled 
study 
Prospecti
ve 
controlled 
study 
Randomized
, double-
blind and 
placebo-
controlled 
study 
Randomized
, double-
blind, 
placebo-
controlled 
study 
Randomized 
double-blind, 
placebo 
controlled 
study 
Randomiz
ed double-
blind, 
placebo-
controlled 
study 
Duration of 
study 
 24 month 24 month 60 month 12 months 6 month 24 month 12 month 12 month 3 month  
(84 days) 
3 month  
(84 days) 
6 month 6 month 
Inclusion 
criteria 
 Healthy 
women 
not being 
treated 
with any 
medicatio
n known 
to affect 
coagulati
on 
fibrinolys
is lipid or 
bone 
metabolis
m and 
with more 
than 10 
years of 
spontaneo
us 
Healthy 
Caucasian 
or Asian 
women 
45years of 
age or 
older, 
within 
80–130% 
of ideal 
body 
weight,1y
ear or 
more but 
4 years or 
less past 
natural 
menopaus
Non-smoking 
women, 
undergoing 
menopause with 
normal BP, 
without 
cardiovascular 
problems and 
osteopenia, but 
with mild 
hypercholesterol
emia  (TC 241+7 
mg/dl; LDL-C 
153+9 mg/dl) 
Postmenopa
usal women 
(≤75 years 
old; BMI 
18–30 
kg/m2) with 
newly 
diagnosed 
and 
histologicall
y confirmed 
invasive or 
non-invasive 
early stage 
breast 
cancer, with 
surgical 
treatment 
Hypertensive 
patients on or 
off treatment 
with 
antihypertens
ive, with 1 or 
more years of 
postmenopau
sal on 
clinical 
grounds 
Patients at 
least 45 
years of age, 
postmenopa
usal for 12 
month or 
more, within 
15% of ideal 
body weight 
or height 
and had 
intact uteri 
and ovaries 
Postmenopa
usal women 
undergoing 
chronic 
hemodialysi
s, with at 
least 6 
months of 
amenorrhea, 
age less than 
65 years, 
and serum 
FSH  
(>20 mIU/L) 
No 
natural 
menstruat
ion for at 
least 12 
months, 
FSH 
 >60 
pg/ml, 
estradiol  
<20  
µg/ml and 
the 
presence 
of 
menopaus
al 
symptoms 
Postmenopa
usal women 
(absence of 
any 
menstrual 
bleeding for 
12 months 
and FSH  
> 50 IU/l 
and estradiol 
< 20 pg/ml), 
45 to 60 
years of age 
with a BMI 
ranging 
between 20 
and 28 
kg/m2 
Healthy 
postmenopa
usal women 
with 
previous 
oophorecto
my or 12 
months 
passed after 
the last 
menstrual 
bleed, FSH 
> 50 IU/l 
and serum 
levels of 
estradiol < 
70 pmol, 
aged 45–60 
Healthy 
women (mean 
age 52.0 ± 
0.34 years) 
who were at 
least 6 months 
beyond a 12 
month period 
of 
hypergonadotr
opic 
amenorrhea 
and had never 
begun HRT 
Healthy 
menopaus
al women 
45–50 
years of 
age who 
had 
undergone 
hysterecto
my and 
bilateral 
salpingo-
oophorec-
tomy as a 
result of 
benign 
diseases 
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menopaus
e 
 
e  and 
without 
osteoporo
sis 
followed by 
tamoxifen 
 years, BMI 
20–28 kg/m2  
Route of 
administrat
ion  
 oral oral oral oral oral oral oral oral oral oral oral oral 
Tibolone 
dose 
 1.25 
mg/day or 
2.5 
mg/day 
 
0.3 
mg/day 
or 
0.625 
mg/day 
or 
1.25 
mg/day 
or 
2.5 
mg/day 
 
2.5 mg/day 
 
2.5 mg/ day 2.5 mg/day 2.5 mg/day 2.5 mg three 
times per 
week 
2.5 
mg/day 
2.5 mg /day 2.5 mg /day 2.5 mg/day 2.5 
mg/day 
Partici-
pants 
Case 29a 132c 53 35e 19 31f 13 20g 12 34 11 28h 
136d 
28b 127a 32b 21b 28b 
131b 
Contr
ol 
13 130 29 35 11 50 13 19 6 31 11 27 
Age (years) Case 66.4 
(7.0)a 
52.3 (2.9)c 49.6±5 58 (6.1)e 60.11 (1.28) 52.4±0.74f 54.5 (4.6) 51.1  ±  
4.1g 
45 - 60  54.5 ± 3.7 51.6±0.49 48±0.6h 
52.8 (3.5)d 
65.5 
(7.5)b 
52.4 (3.2)a 53.6±0.77b 53.4  ±  
3.6b 
46±3b 
52.1 (3.3)b 
Contr
ol 
68.4 (6.1) 52.6 (3.4) 48.4±4 59 (5.5) 62.73 (1.79) 55.6±0.61 56.0 (7.4) 52.7  ±  
3.3 
45 - 60 53·5 ± 3·7 52.1±0.44 47± 0.6 
Male (%) Case 0a 0c 0 0e 0 0f 0 0g 0 0 0 0h 
0d 
0b 0a 0b 0b 0b 
0b 
Contr
ol 
0 0 0 0 0 0 0 0 0 0 0 0 
BMI 
(kg/m2) 
Case 24.5 
(3.4)a 
24.8 (3.8)c 22–26 24.8 (3.2)e* 33.90 (5.99) 41.1± 0.6f 23.9 (4.0) 24  ±  2.7g 20-28  24.5 ± 2.5 21.2±0.32 25.4± 0.3h 
24.8 (3.6)d 
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23.1 
(2.8)b 
25.5 (3.5)a 39.6± 0.7b 25.2  ±  
2.6b 
24.4± 0.7b 
25.2 (3.7)b 
Contr
ol 
24.7 (3.2) 25.4 (3.8) 22–25 25.4 (3.7) 29.60 (1.30) 39.2± 0.5 21.2 (3.0) 23.2  8  
2.6 
20-28  23.7 ± 2.7 20.9±0.22 25.1± 0.1 
prevalence 
of diabetes 
mellitus 
(%) 
Case NSa 0c NS NSe NS NSf 0 NSg NS 0 NS 0h 
0d 
NSb 0a NSb NSb 0b 
0b 
Contr
ol 
NS 0 NS NS NS NS 0 NS NS 0 NS 0 
Lp(a) 
(mg/dL) 
Case 23.1 
(12.6–
44.9)a 
NSc 25±4  20.4 
(25.1)e** 
 
10 (7.5–23)  14.1 (0.9-
106.1)f 
19 (8–117)  28.0 
(24.4)g  
45 (2-229)  27 ± 32 
 
37.5±3.3  35.9 ± 
20.8 h 
 
NSd 
25.8 
(8.95–
36.9)b 
NSa 39.4 (1.6-
122.4)b 
26.7 
(17.1)b 
38.5± 17.8 
b NSb 
Contr
ol 
24.3 
(16.6–
51.2) 
NS 26±5 17.8 
(23.9)** 
14 (5–66) 12.6 (0.6-
87.5) 
16 (8–84) 28.6 
(22.0) 
17 (3-84) 27 ± 34 35.8±5.6 39.8 ± 
18.2  
Values are expressed as mean ± SD or median (25–75 percentiles).  
ABBREVIATIONS: BMI: body mass index; BP: blood pressure; NS: not stated; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; DM: diabetes mellitus; FSH: serum levels 
of follicle stimulating hormone; HRT: hormonal replacement therapy;  adenotes 1.25 mg/day tibolone; bdenotes 2.5 mg/day tibolone; cdenotes 0.3 mg/day tibolone; ddenotes 0.625  mg/day 
tibolone; edenotes 20 mg/day oral tamoxifen (Nolvadex-D; Astra-Zeneca) plus either 2.5 mg/ day oral tibolone (Livial; NVOrganon), fdenotes a combined estrogen (0.625 mg/day) – 
progestin (0.15 mg for 12 days in 28) preparation; g denotes oral medroxyprogesterone acetate (MPA; 10 mg/day for 12 days); hdenotes conjugated ET (Premarin, 0.625 mg/d oral tablets; 
Wyeth, Istanbul, Turkey); *denotes patients belonging to tibolone group n = 34; ** denotes patients belonging to tibolone group or placebo group n = 29. 
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Table 2. Risk of bias assessment in the studies considered for meta-analysis.  
Study Ref SEQUENCE 
GENERATION 
 
ALLOCATION 
CONCEALMENT 
 
BLINDING OF 
PARTICIPANTS 
AND PERSONNEL 
 
BLINDING OF 
OUTCOME 
ASSESSMENT 
 
INCOMPLETE 
OUTCOME 
DATA 
 
SELECTIVE 
OUTCOME 
REPORTING 
 
OTHER 
POTENTIAL 
THREATS TO 
VALIDITY 
 
Bjarnason et al.  33
 U U L L L L L 
Gallagher et al.  34
 U H L L L L L 
Kalogeropoulos et al.  35
 U U U U L L L 
Kroiss et al.  36
 L L L L L L L 
Lloyd et al.  37
 U U L L L L L 
Milner et al.  38
 L U U U L L L 
Ostberg et al.  39
 U U U U L L L 
Perrone et al.  40
 U U U U L L L 
von Eckardstein et al.  41
 U U L L L L L 
von Eckardstein et al.  42 U U L L L L L 
Anedda et al.  43 U U L L L L L 
Demirol et al.  44 U U L L L L L 
L: low risk of bias; H: high risk of bias; U: unclear risk of bias 
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FIGURE LEGENDS  
Figure 1. Flow chart of the number of studies included to the meta-analysis.  
Figure 2. Forest plot displaying weighted mean difference and 95% confidence intervals for the 
impact of tibolone on circulating Lp(a) levels. Lower plot shows leave-one-out sensitivity analysis. 
Figure 3. Forest plot displaying weighted mean difference and 95% confidence intervals for the 
impact of tibolone on circulating Lp(a) levels in trials administering doses < 2.5 mg/day (upper 
plot) and ≥ 2.5 mg/day (lower plot).  
Figure 4. Forest plot displaying weighted mean difference and 95% confidence intervals for the 
impact of tibolone on circulating Lp(a) levels in trials lasting < 24 months (upper plot) and ≥ 24 
months (lower plot).  
Figure 5. Meta-regression plots of the association between mean changes in circulating Lp(a) 
levels s and dose and duration of treatment with tibolone. The size of each circle is inversely 
proportional to the variance of change. 
Figure 6. Funnel plot detailing publication bias in the studies reporting the impact of tibolone on 
circulating Lp(a) levels. Open diamond represents observed effect size; closed diamond represents 
imputed effect size. 
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HIGHLIGHTS:  
 
• Circulating Lp(a) is a recognized risk factor for cardiovascular disease (CVD).  
• Tibolone may lower Lp(a), however, evidence of this effect remains to be confirmed. 
• Meta-analysis suggests a significant Lp(a) reduction following tibolone (by 25.28%). 
• Further studies are warranted to explore the mechanism of this effect.  
• A place of tibolone in individuals at CVD risk needs to be further investigated.  
